Such an evaluation should be undertaken only after other causes of oligomenorrhea have been excluded by proper evaluation of factors such as TSH, prolactin, and 17-OHP, and possibly FSH and LH, in accordance with the 2023 International Guidelines [8]. This evidence concerns the gene BRD2 and Oligomenorrhea.